Brad Hively Sells 298,853 Shares of Oncology Institute (NASDAQ:STLN) Stock

Oncology Institute, Inc. (NASDAQ:STLN) Director Brad Hively sold 298,853 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the completion of the sale, the director directly owned 411,976 shares of the company’s stock, valued at approximately $2,681,963.76. This trade represents a 42.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oncology Institute Stock Performance

NASDAQ STLN opened at $6.30 on Wednesday. Oncology Institute, Inc. has a 1 year low of $2.32 and a 1 year high of $7.05.

Oncology Institute (NASDAQ:STLN) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $161.28 million during the quarter, compared to the consensus estimate of $152.80 million. Sell-side analysts predict that Oncology Institute, Inc. will post -0.21 EPS for the current year.

Hedge Funds Weigh In On Oncology Institute

An institutional investor recently bought a new stake in Oncology Institute stock. AXQ Capital LP acquired a new position in shares of Oncology Institute, Inc. (NASDAQ:STLN) in the second quarter, according to its most recent disclosure with the SEC. The firm acquired 22,460 shares of the company’s stock, valued at approximately $122,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings initiated coverage on Oncology Institute in a research note on Thursday, August 6th. They issued a “sell (d-)” rating for the company. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

About Oncology Institute

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.